Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
2(25%)
Results Posted
100%(3 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_3
1
13%
Ph phase_1
2
25%
Ph phase_2
5
63%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
Active, not recruiting1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 25 (62.5%)
Phase 31 (12.5%)

Trials by Status

active_not_recruiting113%
recruiting113%
unknown113%
completed338%
terminated225%

Recent Activity

2 active trials
Showing 5 of 8
recruitingphase_2

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

NCT02579967
active_not_recruitingphase_2

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

NCT03663933
completedphase_2

Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning

NCT00466674
unknownphase_1

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

NCT02098512
completedphase_2

Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant

NCT00143845
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02579967Phase 2

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Recruiting
NCT03663933Phase 2

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Active Not Recruiting
NCT00466674Phase 2

Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning

Completed
NCT02098512Phase 1

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Unknown
NCT00143845Phase 2

Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant

Completed
NCT01203228Phase 3

Dose-reduced Versus Standard Conditioning in MDS/sAML

Terminated
NCT00744692Phase 1

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

Completed
NCT00143884Phase 2

Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8